Study: Ureteral injury during robot-assisted prostate surgery

November 19, 2013

DETROIT - There may be warning signs to help surgeons avoid damaging part of the urinary system during robot-assisted surgical removal of prostate cancer, ultimately preventing the expense of additional surgery, according to researchers at Henry Ford's Vattikuti Urology Institute.

Although rare, they found instances when the ureter - tubes that carry urine from the kidneys to the bladder - were cut and required repair. In each case, they identified patient characteristics that may forewarn such damage. The study was recently published in the Journal of Endourology.

The study -drawing from Henry Ford Hospital's experience with robot-assisted surgery removal of prostate cancer- was conducted in the context of a steady rise in robot-assisted prostatectomies in the U.S. during the past decade.

Robotics permit surgeons to better visualize anatomy, control bleeding, have greater dexterity, and treat prostate cancers more effectively without complications than was previously possible in traditional open surgery.

While practitioners have reported various complications during the procedure, little data existed prior to this study regarding injuries to the ureter during robotic prostatectomy.

Under guidance of Drs. Mani Menon and James Peabody, a research team at Henry Ford's Vattikuti Urology Institute focused on 6,442 consecutive patients who underwent robotic prostatectomy by one of five surgeons at the hospital from January 2001 to June 2013.

"We found three patients in the study group, operated on by two of the five surgeons, who sustained complete transection of the ureter, although these surgeons were highly experienced, having performed more than 1,000 robotic prostatectomies," says Jay Jhaveri, M.D., M.P.H., lead author of the study. "This is well beyond the accepted learning curve of 100 cases."

"One of the patients required readmission for further treatment, and we were able to identify risk factors that predisposed all of them to ureteral injury."

Among them were a history of infection, abdominal surgery, radiation treatment, enlarged prostate glands and prior transurethral resection of the prostate, in which prostate tissue is surgically trimmed to remove urine flow blockage.

"This knowledge can help identify future patients who are at high risk of sustaining ureteral injury during robotic removal of a cancerous prostate gland," Dr. Jhaveri says. "Measures can then be taken either before or during surgery to reduce the probability of such injury."

The study concluded that despite its relatively rare occurrence, previous studies have isolated trends for patients who are at high risk for ureteral injury during prostatectomy. All of the Henry Ford patients had previous abdominal surgery and none of their injuries were noted intraoperatively.

"We found a 0.046% rate of ureteral injury during robotic prostatectomy which compares favorably with other similar studies and published data for this topic," Dr. Jhaveri says.

Besides the clear benefits to the patients, the study shows such preventive measures can also help avoid prolonged, expensive hospitalization, need for additional treatment or surgery, as well as the costs of follow-up treatments.
-end-
For a copy of the study, please email Dwight.angell@hfhs.org

Henry Ford Health System

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.